Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PGD | P52209 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27825801 | 0.89 | OR51E2 (0.40) | PDE4APGDOR51E2LMNAKDM4E | |
| SCHEMBL3692445 | 0.79 | PDE4A (0.48) | PDE4AOR51E2LMNAKDM4EDUSP3 | |
| SCHEMBL27926540 | 0.77 | KDM4E (0.33) | PGDTSHROR51E2LMNAKDM4E | |
| SCHEMBL27805163 | 0.77 | OR51E2 (0.31) | OR51E2LMNAKDM4EDUSP3MEN1 | |
| SCHEMBL3979990 | 0.77 | PGD (0.42) | PGDTSHRCYP2C9 | |
| Potassium Ion SCHEMBL515474 | 0.76 | LMNA (0.38) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL3808120 | 0.76 | OR51E2 (0.40) | PDE4AOR51E2LMNAKDM4EDUSP3 | |
| SCHEMBL3809261 | 0.76 | OR51E2 (0.40) | PDE4AOR51E2LMNAKDM4EDUSP3 | |
| SCHEMBL7529189 | 0.76 | OR51E2 (0.40) | PDE4AOR51E2LMNAKDM4EDUSP3 | |
| SCHEMBL234927 | 0.74 | TSHR (0.39) | PDE4APGDTSHROR51E2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4306298-A | — | — | None | — | — | JP | disclosed |
| JP-4353600-A | — | — | None | — | — | JP | disclosed |
| CN-115594808-B | Bio-based anionic waterborne polyurethane and preparation method and application thereof | 亚士防水科技(滁州)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115927028-A | Transformation vector containing lignin lyase gene, engineering bacterium and application of transformation vector | 临沂大学 | 2023-04-07 | — | — | CN | disclosed |
| WO-2023053997-A1 | METHOD FOR PRODUCING OIL WITH BROILED FRESHWATER EEL FLAVOR, METHOD FOR PRODUCING FOOD WITH BROILED FRESHWATER EEL FLAVOR, AND METHOD FOR IMPARTING BROILED FRESHWATER EEL FLAVOR TO EDIBLE OIL/FAT | 株式会社Ｊ－オイルミルズ | 2023-04-06 | — | — | WO | disclosed |
| EP-3890695-A1 | USE OF POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR | Momentive Performance Materials Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3891204-A1 | POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR | Momentive Performance Materials Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| US-11090255-B2 | Use of polycarboxylic acid compounds for the treatment of fibrious amino acid based substrates, especially hair | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2020117516-A1 | USE OF POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117509-A1 | POLYCARBOXYLIC ACID COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES, ESPECIALLY HAIR | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2006029525-A1 | THE USE OF AN INHIBITOR OF HETEROTETRAMERIC ANNEXIN 2 FOR TREATING VIRAL INFECTIONS | CANADIAN BLOOD SERVICES (CA) | 2006-03-23 | — | — | WO | disclosed |
| US-20060057591-A1 | Method for preventing viral infection | CANADIAN BLOOD SERVICES (CA) | 2006-03-16 | — | — | US | disclosed |
| US-6849610-B1 | Polynucleotide ligands as anti-viral agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-01 | — | — | US | disclosed |
| CN-1443057-A | Decorative cosmetic preparations containing dialkyl carbonates and metal oxides | COGNIS DEUTSCHLAND GMBH (DE) | 2003-09-17 | — | — | CN | disclosed |
| CN-1440271-A | Deodorant containing dialkyl carbonate and propellant and its use as aerosol | COGNIC DEUTSCHLAND GMBH & CO K (DE) | 2003-09-03 | — | — | CN | disclosed |
| CN-1398179-A | Cosmetic prepns. contg. waltheria indica extracts | COGIS FRANCE S A (FR) | 2003-02-19 | — | — | CN | disclosed |
| CN-1379655-A | Decorative cosmetic preparations containing chitosan microcapsules charged with active ingredients | PRIMACARE S A (ES) | 2002-11-13 | — | — | CN | disclosed |
| WO-2001038341-A1 | POLYNUCLEOTIDE LIGANDS AS ANTI-VIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-31 | — | — | WO | disclosed |
| JP-H04353600-A | DRY-FINISHING AGENT COMPOSITION | KAO CORP | 1992-12-08 | — | — | JP | disclosed |
| JP-H04306298-A | DRY FINISHING AGENT COMPOSITION | KAO CORP | 1992-10-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090255-B2 | Use of polycarboxylic acid compounds for the treatment of fibrious amino acid based substrates, especially hair | ABAT, PCCA, FH | PDE4A 4394/4885PGD 273/4885TSHR 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.